Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA)

Journal of Liposome Research

Volumn 17, Issue 3-4, 2007, Pages 191-196

  Foged, Camilla ^a   Nielsen, Hanne M ^a   Frokjaer, Sven ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Liposomes; Phospholipase A2; RNA interference; siRNA

Indexed keywords

LIPOSOME; MACROGOL; PHOSPHOLIPASE A2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CATALYSIS; CONFERENCE PAPER; ENDOSOME; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MAMMAL CELL; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHEUMATOID ARTHRITIS; RNA INTERFERENCE;

ARTHRITIS, RHEUMATOID; HUMANS; LIPOSOMES; PERMEABILITY; PHOSPHOLIPASES A2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 36248946723     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100701530373     Document Type: Conference Paper

References (35)

1. Abe, T., Sakamoto, K., et al. (1997). Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int. J. Cancer 74:245-250.
2. Andresen, T. L., Jensen, S. S., Jorgensen, K. (2005). Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lip. Res. 44:68-97.
3. Bernstein, E., Caudy, A. A., et al. (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.
4. Bezzine, S., Bollinger, J. G., et al. (2002). On the binding preference of human groups IIA and X phospholipases A(2) for membranes with anionic phospholipids. J. Biol. Chem. 277:48523-48534.
5. Bitko, V., Musiyenko, A., et al. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11:50-55.
6. Davidsen, J., Mouritsen, O. G., Jorgensen, K. (2002). Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes. Biochim. Biophys. Acta 1564:256-262.
7. Dennis, E. A. (1994). Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. 269:13057-13060.
8. Dykxhoorn, D. M., Palliser, D., Lieberman, J. (2006). The silent treatment: siRNAs as small molecule drugs. Gene Ther. 13:541-552.
9. Elbashir, S. M., Harborth, J., et al. (2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
10. Elbashir, S. M., Lendeckel, W., Tuschl, T. (2001b). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200.
11. Fire, A., Xu, S., et al. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
12. Foged, C., Nielsen, H. M., Frokjaer, S. (2007). Liposomes for phospholipase A2 triggered siRNA release: Preparation and in vitro test. Int. J. Pharm. 331:160-166.
13. Halperin, A., Mouritsen, O. G. (2005). Role of lipid protrusions in the function of interfacial enzymes. Eur. Biophys. J. 34:967-971.
14. Inoue, A., Takahashi, K. A., et al. (2005). Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem. Biophys. Res. Com. 336:903-908.
15. Jain, M. K., Berg, O. G. (2006). Coupling of the i-face and the active site of phospholipase A(2) for interfacial activation. Curr. Opin. Chem. Biol. 10:473-479.
16. Kim, D. H., Rossi, J. J. (2007). Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8:173-184.
17. Lawrence, R. C., Helmick, C. G., et al. (1998). Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis. Rheum. 41:778-799.
18. Mahato, R. I., Anwer, K., et al. (1998). Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum. Gene Ther. 9:2083-2099.
19. McFarland, T. J., Zhang, Y., et al. (2004). Gene therapy for proliferative ocular diseases. Expert Opin. Biol. Ther. 4:1053-1058.
20. Medina-Kauwe, L. K., Xie, J., Hamm-Alvarez, S. (2005). Intracellular trafficking of nonviral vectors. Gene Ther. 12:1734-1751.
21. Menschikowski, M., Hagelgans, A., Siegert, G. (2006). Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 79:1-33.
22. Orban, T. I., Izaurralde, E. (2005). Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11:459-469.
23. Pai, S. I., Lin, Y. Y., et al. (2006). Prospects of RNA interference therapy for cancer. Gene Ther. 13:464-477.
24. Paulos, C. M., Turk, M. J., et al. (2004). Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev. 56:1205-1217.
25. Raoul, C., Barker, S. D., Aebischer, P. (2006). Viral-based modelling and correction of neurodegenerative diseases by RNA interference. Gene Ther. 13:487-495.
26. Rossi, J. J. (2006). RNAi as a treatment for HIV-1 infection. Biotechniques Suppl:25-29.
27. Schiffelers, R. M., Banciu, M., et al. (2006). Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J. Liposome Res. 16:185-194.
28. Schiffelers, R. M., Woodle, M. C., Scaria, P. (2004). Pharmaceutical prospects for RNA interference. Pharm. Res. 21:1-7.
29. Schiffelers, R. M., Xu, J., et al. (2005). Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis. Rheum. 52:1314-1318.
30. Seilhamer, J. J., Pruzanski, W., et al. (1989). Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. 264:5335-5338.
31. Vermehren, C., Kiebler, T., et al. (1998). Increase in phospholipase A2 activity towards lipopolymer-containing liposomes. Biochim. Biophys. Acta 1373:27-36.
32. Winget, J. M., Pan, Y. H., Bahnson, B. J. (2006). The interfacial binding surface of phospholipase A2s. Biochim. Biophys. Acta 1761:1260-1269.
33. Yamashita, S., Ogawa, M. et al. (1994). Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin. Chim. Acta 228:91-99.
34. Zamore, P. D., Tuschl, T. et al. (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25-33.
35. Zimmermann, T. S., Lee, A. C. H., et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441:111-114.